Biotech Breakthroughs: 3 Stocks on the Verge of Revolutionizing Medicine

Biotech breakthrough stocks, along with the sector overall, faced significant challenges over the past two years, with venture capital drying up, shifts in the post-pandemic healthcare landscape and tighter regulatory conditions squeezing already-thin margins. However, 2024 may herald a resurgence for biotech stocks, spurred by an FDA approval spree throughout 2023. Last year, the FDA approved 55 treatment protocols that included previously unapproved ingredients or compounds, a significant increase from th ...